Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01393106 | Safety and Efficacy of Idelalisib in Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00129753 | Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT01499147 | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies | completed | N/A | 100 | University of Illinois at ChicagoOTHER | 1 | Nov 8, 2018 | clinicaltrials |
| NCT01965119 | Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma(JAK2) | completed | Phase 2 | 20 | Samsung Medical CenterOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT00038558 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | completed | Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01569204 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | completed | Phase 2 | 100 | University of CologneOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03323541 | Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure(ZAPA) | completed | — | 62 | University Hospital, BrestOTHER | 0 | Sep 21, 2018 | clinicaltrials |
| NCT03107663 | ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma | completed | Phase 1 | 15 | ImaginAb, Inc.INDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00982449 | 124I-FIAU Imaging in EBV and KSHV Associated Cancers | completed | N/A | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT02795013 | Genetic Study of Families With High Frequency of Hodgkin Lymphoma | completed | — | 27 | St. Jude Children's Research HospitalOTHER | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT03664323 | Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma | completed | — | 30 | Hospices Civils de LyonOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00754286 | A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer | completed | N/A | 132 | Albert Einstein College of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT02800447 | Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol | unknown | N/A | 92 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Sep 4, 2018 | clinicaltrials |
| NCT00901303 | Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma | terminated | N/A | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | completed | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01877005 | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma(HIJAK) | completed | Phase 2 | 33 | The Lymphoma Academic Research OrganisationOTHER | 2 | Aug 22, 2018 | clinicaltrials |
| NCT00484874 | Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 12 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03602131 | Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma | unknown | Phase 2 | 30 | Sichuan UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT00026208 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | completed | Phase 2 | 76 | Stanford UniversityOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01326728 | Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | — | 56 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT03540849 | BV After Allogeneic Hematopoietic Stem Cell Transplantation(BV-ALLO) | unknown | Phase 2 | 58 | University Hospital, CaenOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT02567851 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity(BREVITY) | completed | Phase 2 | 38 | University of BirminghamOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00385788 | Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease | completed | Phase 2 | 52 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 2, 2018 | clinicaltrials |
| NCT01393717 | Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma | completed | Phase 2 | 57 | City of Hope Medical CenterOTHER | 1 | Apr 26, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT00952237 | Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF | completed | Phase 1 | 13 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00909948 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant(RLI) | terminated | Phase 1 | 7 | Massachusetts General HospitalOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT01056679 | Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients(AVD-Rev) | completed | Phase 1 | 30 | University of CologneOTHER | 1 | Mar 22, 2018 | clinicaltrials |
| NCT03469921 | Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016(HEMAJA) | completed | — | 602 | Institut Paoli-CalmettesOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT01820117 | Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation | completed | — | 416 | St. Jude Children's Research HospitalOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT01534078 | Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma | completed | Phase 2 | 34 | Massachusetts General HospitalOTHER | 1 | Feb 20, 2018 | clinicaltrials |
| NCT01969435 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | completed | Phase 2 | 50 | Washington University School of MedicineOTHER | 1 | Feb 13, 2018 | clinicaltrials |
| NCT02244021 | BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV | completed | Phase 2 | 13 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Nov 21, 2018source: clinicaltrials